Efficacy and Safety of Extract of Gelidium Elegans

Double Blind, Randomized Controlled Study to Evaluate the Efficacy and Safety of Extract of Gelidium Elegans

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03842774

Enrollment

Registered

2019-02-15

Start date

2017-11-08

Completion date

2018-11-23

Last updated

2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

Extract of Gelidium elegans inhibits lipid differentiation, accumulation, and synthesis in vitro and in vivo. It has also anti-obesity effect by inhibiting weight gain and decreasing body fat. In a preliminary study of obese adults aged 20 years or older, the extracts of Gelidium elegans showed a tendency to decrease in body fat and visceral fat, and to increase lean body mass. Based on these results, we tried to confirm the effect of body weight and body fat reduction of Gelidium elegans extract in overweight and obese people.

Interventions

DIETARY_SUPPLEMENTExract of Gelidium elegans

Exract of Gelidium elegans will be given to the test group.

DIETARY_SUPPLEMENTPlacebo

Placebo supplement will be given to the test group.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 50 Years

Healthy volunteers

Inclusion criteria

* 1\. Between the ages of 19 and 50 * 2\. BMI is at or greater than 23 and less than 30 kg/m\^2

Exclusion criteria

* 1\. uncontrolled hypertension * 2\. uncontrolled diabetes * 3\. current serious cerebrovascular and cardiovascular disease

Design outcomes

Primary

Measure	Time frame
change in body fat mass by DEXA after 12-week treatment	12 week
change in visceral, subcutaneous, total fat area and ratio of visceral and subcutaneous fat area will be combined to report by Fat CT after 12-week treatment	12 week

Secondary

Measure	Time frame
change in hip circumference	6 week
change in ratio of waist and hip circumference	6 week
body mass index	6 week
change in lean body mass by DEXA	6 week
change in body weight and body fat mass will be combined to report by Bio-impedance	6 week
change in laboratory test result of CRP	6 week
change in laboratory test result of fasting insulin	6 week
change in HOMA-IR	6 week
change in HOMA-beta	6 week
change in laboratory test result of total cholesterol, HDL, LDL and triglyceride will be combined to report as lipid profile	6 week
change in waist circumference	6 week

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026